$0.61
8.97% day before yesterday
Nasdaq, Jul 11, 10:00 pm CET
ISIN
US75955J2042
Symbol
RLMD
Sector
Industry

Relmada Therapeutics Inc Stock price

$0.61
-0.16 20.42% 1M
+0.21 50.99% 6M
+0.09 17.31% YTD
-3.75 86.01% 1Y
-18.47 96.80% 3Y
-39.77 98.49% 5Y
-32.39 98.15% 10Y
-59.39 98.98% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.06 8.97%
ISIN
US75955J2042
Symbol
RLMD
Sector
Industry

Key metrics

Basic
Market capitalization
$20.3m
Enterprise Value
$-6.8m
Net debt
positive
Cash
$27.1m
Shares outstanding
33.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.1
P/B
0.9
Financial Health
Equity Ratio
77.5%
Return on Equity
-225.2%
ROCE
-352.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-105.6m
EBIT
$-79.1m | $-61.1m
Net Income
$-75.7m | $-65.3m
Free Cash Flow
$-56.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
19.7% | 27.2%
Net Income
19.7% | 18.3%
Free Cash Flow
-17.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.5
FCF per Share
$-1.7
Short interest
2.1%
Employees
17
Rev per Employee
$0.0
Show more

Is Relmada Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Relmada Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Relmada Therapeutics Inc forecast:

5x Hold
63%
3x Sell
38%

Analyst Opinions

8 Analysts have issued a Relmada Therapeutics Inc forecast:

Hold
63%
Sell
38%

Financial data from Relmada Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
26% 26%
-
- Research and Development Expense 45 45
14% 14%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -79 -79
20% 20%
-
Net Profit -76 -76
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Relmada Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relmada Therapeutics Inc Stock News

Neutral
GlobeNewsWire
4 days ago
Appointment highlights DIMERx's next phase of growth as it advances non-addictive pain therapeutics with support from the NIH HEAL Initiative Appointment highlights DIMERx's next phase of growth as it advances non-addictive pain therapeutics with support from the NIH HEAL Initiative
Neutral
GlobeNewsWire
26 days ago
Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and centra...
Neutral
Seeking Alpha
2 months ago
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2025 Earnings Call May 12, 2025 4:30 PM ET Company Participants Brian Ritchie - Investor Relations Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Yair Lotan - Chief, Urology and Oncology Conference Call Participants Uy Ear - Mizuho Securities Matt Barcus - Jefferies Operator Good afternoon. Welcome to the Relmada T...
More Relmada Therapeutics Inc News

Company Profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.

Head office United States
CEO Sergio Traversa
Employees 17
Founded 2012
Website www.relmada.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today